PTEN and melanoma: Next, to both validate response data and develop a more tractable in vitro system to understand the role of PREX2 under treatment, we used CRISPR/Cas9-mediated gene editing to disrupt the expression of PREX2 or its close relative PREX1 in the PTEN-deficient WM266.4 melanoma line.